Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline Market, Trends, Share, Size Research Report

Home
Pharmaceutical
Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

Publisher Name » GBI Research

Published Date » 2012-07-10

GBI Research, the leading business intelligence provider, has released its latest research, Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 20072011 and found that competitive activity is increasing in the oncology therapeutics market.

Scope

Data and analysis on the leading therapeutic classes in oncology.
Market data on the promising molecules in the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer.
Key M&A activities and licensing agreements that took place from 20052011 in the oncology market.

Reasons to buy

Align your product portfolio to markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12

2 Novel Therapies in Oncology - Introduction 15

3 Novel Therapies in Oncology - Key Innovations and Technologies 16
3.1 Introduction 16
3.1.1 Increase in Cancer 17
3.1.2 Risk Factors for Cancer 17
3.2 Oncology Treatment Pathways 17
3.2.1 Chemotherapeutics 17
3.2.2 Targeted Therapies 18
3.3 Leading Marketed Drugs in Oncology 18
3.3.1 Rituxan/ MabThera 18
3.3.2 Herceptin 19
3.3.3 Gleevec/Glivec 20
3.3.4 Avastin 21
3.3.5 Eloxatin 21
3.3.6 Erbitux 22
3.3.7 Xeloda 22
3.3.8 Femara 23
3.3.9 Temodar 23
3.3.10 Tarceva 24
3.3.11 Taxotere 25
3.3.12 Revlimid 25
3.3.13 Alimta 26

4 Novel Therapies in Oncology - Leading Novel Drug Classes for the Future 27
4.1 Protein Kinase Inhibitors 27
4.2 Vaccines 28
4.2.1 Tumor Cell Vaccines 29
4.2.2 Antigen Vaccines 29
4.2.3 Dendritic Cell Vaccines 30
4.2.4 Anti-Idiotype vaccines 30

5 Novel Therapies in Oncology - Opportunity and Unmet Need Analysis 31
5.1 Breast Cancer 31
5.2 Colorectal Cancer 33
5.3 NHL 34
5.4 NSCLC 36
5.5 Prostate Cancer 38
5.6 Ovarian Cancer 39
5.7 Cervical Cancer 40
5.8 Head and Neck Cancer 41

6 Novel Therapies in Oncology - Product Pipeline Analysis 43
6.1 Introduction 43
6.2 Breast Cancer 47
6.2.1 Breast Cancer Pipeline - Introduction 47
6.2.2 Breast Cancer Pipeline - Analysis by Therapeutic Class 48
6.2.3 Breast Cancer Pipeline - Pre-Clinical 53
6.2.4 Breast Cancer Pipeline - Discovery 54
6.2.5 Breast Cancer Pipeline - Phase I 55
6.2.6 Breast Cancer Pipeline - Phase II 57
6.2.7 Breast Cancer Pipeline - Phase III 61
6.2.8 Breast Cancer Pipeline - NDA Filed 61
6.3 Colorectal Cancer 62
6.3.1 Colorectal Cancer Pipeline - Introduction 62
6.3.2 Colorectal Cancer Pipeline - Analysis by Therapeutic Class 63
6.3.3 Colorectal Cancer Pipeline - Pre-Clinical 68
6.3.4 Colorectal Cancer Pipeline - Discovery 68
6.3.5 Colorectal Cancer Pipeline - Phase I 69
6.3.6 Colorectal Cancer Pipeline - Phase II 71
6.3.7 Colorectal Cancer Pipeline - Phase III 74
6.4 NHL 75
6.4.1 NHL Pipeline - Introduction 75
6.4.2 NHL Pipeline - Analysis by Therapeutic Class 76
6.4.3 NHL Pipeline - Pre-Clinical 81
6.4.4 NHL Pipeline - Discovery 81
6.4.5 NHL Pipeline - Phase I 82
6.4.6 NHL Pipeline - Phase II 84
6.4.7 NHL Pipeline - Phase III 85
6.4.8 NHL Pipeline - NDA Filed 85
6.5 NSCLC 86
6.5.1 NSCLC Pipeline - Introduction 86
6.5.2 NSCLC Pipeline - Analysis by Therapeutic Class 87
6.5.3 NSCLC Pipeline - Pre-Clinical 93
6.5.4 NSCLC Pipeline - Discovery 94
6.5.5 NSCLC Pipeline - Phase I 94
6.5.6 NSCLC Pipeline - Phase II 95
6.5.7 NSCLC Pipeline - Phase III 97
6.5.8 NSCLC Pipeline - NDA Filed 98
6.6 Prostate Cancer 99
6.6.1 Prostate Cancer Pipeline - Introduction 99
6.6.2 Prostate Cancer Pipeline - Analysis by Therapeutic Class 100
6.6.3 Prostate Cancer Pipeline - Pre-Clinical 106
6.6.4 Prostate Cancer Pipeline - Discovery 107
6.6.5 Prostate Cancer Pipeline - Phase I 108
6.6.6 Prostate Cancer Pipeline - Phase II 109
6.6.7 Prostate Cancer Pipeline - Phase III 111
6.6.8 Prostate Cancer Pipeline - NDA Filed 112
6.7 Ovarian Cancer 112
6.7.1 Ovarian Cancer Pipeline - Introduction 112
6.7.2 Ovarian Cancer Pipeline - Analysis by Therapeutic Class 113
6.7.3 Ovarian Cancer Pipeline - Pre-Clinical 117
6.7.4 Ovarian Cancer Pipeline - Discovery 118
6.7.5 Ovarian Cancer Pipeline - Phase I 119
6.7.6 Ovarian Cancer Pipeline - Phase II 120
6.7.7 Ovarian Cancer Pipeline - Phase III 122
6.7.8 Ovarian Cancer Pipeline - NDA Filed 122
6.8 Cervical Cancer 123
6.8.1 Cervical Cancer Pipeline - Introduction 123
6.8.2 Cervical Cancer Pipeline - Analysis by Therapeutic Class 124
6.8.3 Cervical Cancer Pipeline - Pre-Clinical 128
6.8.4 Cervical Cancer Pipeline - Phase I 128
6.8.5 Cervical Cancer Pipeline - Phase II 129
6.8.6 Cervical Cancer Pipeline - Phase III 129
6.9 Head and Neck Cancer 130
6.9.1 Head and Neck Cancer Pipeline - Introduction 130
6.9.2 Head and Neck Cancer Pipeline - Analysis by Therapeutic Class 131
6.9.3 Head and Neck Cancer Pipeline - Pre-Clinical 135
6.9.4 Head and Neck Cancer Pipeline - Discovery 135
6.9.5 Head and Neck Cancer Pipeline - Phase I 136
6.9.6 Head and Neck Cancer Pipeline - Phase II 137
6.9.7 Head and Neck Cancer Pipeline - Phase III 139

7 Novel Therapies In Oncology - Promising Molecules 140
7.1 T-DM1 140
7.1.1 Introduction 140
7.1.2 Mechanism of Action 140
7.1.3 Revenues 140
7.2 Afinitor (everolimus) 141
7.2.1 Introduction 141
7.2.2 Mechanism of Action 141
7.2.3 Revenues 142
7.3 Iniparib (E75) 143
7.3.1 Introduction 143
7.3.2 Mechanism of Action 143
7.3.3 Revenues 144
7.4 Afatinib 145
7.4.1 Introduction 145
7.4.2 Mechanism of Action 145
7.4.3 Revenues 145
7.5 Avastin 146
7.5.1 Introduction 146
7.5.2 Mechanism of Action 146
7.5.3 Revenues 146
7.6 Farletuzumab 147
7.6.1 Introduction 147
7.6.2 Mechanism of Action 147
7.6.3 Revenues 148
7.7 V503 149
7.7.1 Introduction 149
7.7.2 Mechanism of Action 149
7.7.3 Revenues 149
7.8 Tykerb 150
7.8.1 Introduction 150
7.8.2 Mechanism of Action 150
7.8.3 Revenues 151
7.9 TheraCIM 152
7.9.1 Introduction 152
7.9.2 Mechanism of Action 152
7.9.3 Revenues 153

8 Novel Therapies In Oncology - Strategic Consolidations 154
8.1 M&A Landscape 154
8.1.1 M&A Deals by Year 156
8.1.2 M&A Deals by Geography 157
8.1.3 M&A Deals by Value 158
8.1.4 M&A Deals by Deal Type 159
8.2 R&D Licensing Agreements 160
8.2.1 Deals by Year 161
8.2.2 Deals by Geography 162
8.2.3 Deals by Value 163
8.3 Co-Development Agreements 164
8.3.1 Deals by Year 165
8.3.2 Deals by Geography 166
8.3.3 Deals by Value 167

9 Novel Therapies In Oncology - Appendix 168
9.1 Market Definitions 168
9.2 Abbreviations 168
9.3 Sources 169
9.4 Research Methodology 170
9.4.1 Coverage 170
9.4.2 Secondary Research 170
9.4.3 Primary Research 171
9.4.4 Section Wise Methodology 171
9.4.5 Expert Panel Validation 171
9.5 Contact Us 172
9.6 Disclaimer 172

List of Tables

Table 1: Novel Therapies in Oncology, Oncology Clinical Trials, 2011 16
Table 2: Novel Therapies in Oncology, Pipeline by Developmental Phase, 2011 43
Table 3: Novel Therapies in Oncology, Pipeline by Indication, 2011 45
Table 4: Novel Therapies in Oncology, Pipeline by Therapeutic Class, 2011 46
Table 5: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase, 2011 47
Table 6: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 48
Table 7: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 49
Table 8: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 50
Table 9: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 51
Table 10: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 52
Table 11: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 53
Table 12: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Stage Molecules, 2011 54
Table 13: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules, 2011 55
Table 14: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules, 2011 57
Table 15: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules, 2011 61
Table 16: Novel Therapies in Oncology, Breast Cancer Pipeline, NDA Filed Molecules, 2011 61
Table 17: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase, 2011 62
Table 18: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 63
Table 19: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 64
Table 20: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class , 2011 65
Table 21: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 66
Table 22: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 67
Table 23: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 68
Table 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Stage Molecules, 2011 68
Table 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules, 2011 69
Table 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules, 2011 71
Table 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules, 2011 74
Table 28: Novel Therapies in Oncology, NHL Pipeline by Phase, 2011 75
Table 29: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 76
Table 30: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class, 2011 77
Table 31: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class, 2011 78
Table 32: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class, 2011 79
Table 33: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class, 2011 80
Table 34: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Stage Molecules, 2011 81
Table 35: Novel Therapies in Oncology, NHL Pipeline, Discovery Stage Molecules, 2011 81
Table 36: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules, 2011 82
Table 37: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules, 2011 84
Table 38: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules, 2011 85
Table 39: Novel Therapies in Oncology, NHL Pipeline, NDA Filed Molecules, 2011 85
Table 40: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase, 2011 86
Table 41: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 87
Table 42: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class, 2011 88
Table 43: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class, 2011 89
Table 44: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class, 2011 90
Table 45: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class, 2011 91
Table 46: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 92
Table 47: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Stage Molecules, 2011 93
Table 48: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Stage Molecules, 2011 94
Table 49: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules, 2011 94
Table 50: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules, 2011 95
Table 51: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules, 2011 97
Table 52: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules, 2011 98
Table 53: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase, 2011 99
Table 54: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 101
Table 55: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 102
Table 56: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 103
Table 57: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 104
Table 58: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 105
Table 59: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 106
Table 60: Novel Therapies in Oncology, Prostate Cancer Pipeline, Discovery Stage Molecules, 2011 107
Table 61: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules, 2011 108
Table 62: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules, 2011 109
Table 63: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules, 2011 111
Table 64: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules, 2011 112
Table 65: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase, 2011 112
Table 66: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 113
Table 67: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class,2011 114
Table 68: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 115
Table 69: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 116
Table 70: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 117
Table 71: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Discovery Stage Molecules, 2011 118
Table 72: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules, 2011 119
Table 73: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules, 2011 120
Table 74: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
Table 75: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
Table 76: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase, 2011 123
Table 77: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 124
Table 78: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 125
Table 79: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 126
Table 80: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 127
Table 81: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 128
Table 82: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules, 2011 128
Table 83: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules, 2011 129
Table 84: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules, 2011 129
Table 85: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase, 2011 130
Table 86: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 131
Table 87: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 131
Table 88: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 132
Table 89: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 133
Table 90: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 134
Table 91: Novel Therapies in Oncology, Head And Neck Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 135
Table 92: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Stage Molecules, 2011 135
Table 93: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules, 2011 136
Table 94: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules, 2011 137
Table 95: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules, 2011 139
Table 96: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
Table 97: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
Table 98: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
Table 99: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
Table 100: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 147
Table 101: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2015-2018 148
Table 102: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
Table 103: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
Table 104: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
Table 105: Novel Therapies in Oncology, Global, Major M&A Deals, 2007-2011 154
Table 106: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
Table 107: Novel Therapies in Oncology, Global, M&A Deals by Geography, 2007-2011 157
Table 108: Novel Therapies in Oncology, Global, M&A Deals by Value, 2007-2011 158
Table 109: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, 2007-2011 159
Table 110: Novel Therapies in Oncology, Global, Major R&D Licensing Deals, 2007-2011 160
Table 111: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
Table 112: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, 2007-2011 162
Table 113: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, 2007-2011 163
Table 114: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 164
Table 115: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
Table 116: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, 2007-2011 166
Table 117: Novel Therapies in Oncology, Global, Co-Development Deals by Value, 2007-2011 167

List of Figures

Figure 1: Novel Therapies in Oncology, Oncology Clinical Trials Share (%), 2011 16
Figure 2: Novel Therapies in Oncology, Protein Kinase Inhibitors Molecules by Indication, 2011 27
Figure 3: Novel Therapies in Oncology, Vaccine Molecules by Indication, 2011 28
Figure 4: Novel Therapies in Oncology, Metastatic Breast Cancer Opportunity and Unmet Need Analysis, 2011 31
Figure 5: Novel Therapies in Oncology, Adjuvant Breast Cancer Opportunity and Unmet Need Analysis, 2011 32
Figure 6: Novel Therapies in Oncology, Colorectal Cancer Opportunity and Unmet Need Analysis, 2011 33
Figure 7: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, First-line Therapy, 2011 34
Figure 8: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, Second line Therapy, 2011 35
Figure 9: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, First line Therapy, 2011 36
Figure 10: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, Second Line Therapy, 2011 37
Figure 11: Novel Therapies in Oncology, Prostate Cancer Opportunity and Unmet Need Analysis, 2011 38
Figure 12: Novel Therapies in Oncology, Ovarian Cancer Opportunity and Unmet Need Analysis, 2011 39
Figure 13: Novel Therapies in Oncology, Cervical Cancer Opportunity and Unmet Need Analysis, 2011 40
Figure 14: Novel Therapies in Oncology, Head and Neck Cancer Opportunity and Unmet Need Analysis, 2011 41
Figure 15: Novel Therapies in Oncology, Pipeline by Developmental Phase (%), 2011 43
Figure 16: Novel Therapies in Oncology, Pipeline by Indication (%), 2011 44
Figure 17: Novel Therapies in Oncology, Pipeline by Therapeutic Class (%), 2011 45
Figure 18: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase (%), 2011 47
Figure 19: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 48
Figure 20: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 49
Figure 21: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 50
Figure 22: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 51
Figure 23: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 52
Figure 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase (%), 2011 62
Figure 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 63
Figure 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 64
Figure 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 65
Figure 28: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 66
Figure 29: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 67
Figure 30: Novel Therapies in Oncology, NHL Pipeline by Phase (%), 2011 75
Figure 31: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 76
Figure 32: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 77
Figure 33: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 78
Figure 34: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 79
Figure 35: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 80
Figure 36: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase (%), 2011 86
Figure 37: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 87
Figure 38: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 88
Figure 39: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 89
Figure 40: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 90
Figure 41: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 91
Figure 42: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 92
Figure 43: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase (%), 2011 99
Figure 44: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 100
Figure 45: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 102
Figure 46: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 103
Figure 47: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 104
Figure 48: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 105
Figure 49: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase (%), 2011 112
Figure 50: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 113
Figure 51: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 114
Figure 52: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 115
Figure 53: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 116
Figure 54: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase (%), 2011 123
Figure 55: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 124
Figure 56: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 125
Figure 57: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 126
Figure 58: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 127
Figure 59: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase (%), 2011 130
Figure 60: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 131
Figure 61: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 132
Figure 62: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 133
Figure 63: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 134
Figure 64: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
Figure 65: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
Figure 66: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
Figure 67: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
Figure 68: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 146
Figure 69: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2014-2018 148
Figure 70: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
Figure 71: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
Figure 72: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
Figure 73: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
Figure 74: Novel Therapies in Oncology, Global, M&A Deals by Geography, (%), 2007-2011 157
Figure 75: Novel Therapies in Oncology, Global, M&A Deals by Value, (%), 2007-2011 158
Figure 76: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, (%), 2007-2011 159
Figure 77: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
Figure 78: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, (%), 2007-2011 162
Figure 79: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, (%), 2007-2011 163
Figure 80: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
Figure 81: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, (%), 2007-2011 166
Figure 82: Novel Therapies in Oncology, Global, Co-Development Deals by Value, (%), 2007-2011 167

Related Reports

Home Healthcare Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

Oct 22, 2012 | By - Transparency Market Research

This report is an effort to identify factors, which will be the driving force behind the home healthcare market and sub-markets in the next few years. The report provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the home healthcare industry in terms of...

Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

Oct 1, 2012 | By - GBI Research

Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth GBI Research, the leading business intelligence provider has released its latest research report, Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support...

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

Nov 1, 2012 | By - GBI Research

Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market GBI Research, the leading business intelligence provider, has released its latest research, Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable...

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

Sep 30, 2012 | By - GBI Research

Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans GBI Research, the leading business intelligence provider has released its latest research report, Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans. The report focuses on the key insights into the biodefense...

e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

Jul 31, 2012 | By - GBI Research

GBI Research, the leading business intelligence provider, has released its latest research, e-Clinical Trial Solutions Market to 2018 Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies, which provides key data and analysis of the major factors affecting the market for eClinical trial solutions in the...

Upcoming Reports:

Content Delivery Network (CDN) - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018

By - Transparency Market Research

CDN stands for “Content Delivery Network.” This network delivers a variety of content mainly video to web browsers, set-top boxes, mobile devices and gaming consoles. It is the basic term in online video or streaming. In the system of distributed servers, the web content and webpages are delivered based on the geographic location of the user, a content delivery server and the origin of the webpage. This system is highly effective in enhancing bandwidth and thus it improves access to the data. CDN comprises of applications, web objects, downloadable data objects,...

Ready To Drink (RTD) Tea And Coffee Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

By - Transparency Market Research

Ready to drink (RTD) tea and coffee is a substitute for carbonated drinks and is widely gaining popularity due to fast and busy lifestyles. RTD tea is especially preferred by consumers who are health conscious, while RTD coffee is perceived as an instant energy source. RTD tea and coffee are one of the most selling products worldwide. The RTD tea and coffee market has shown remarkable growth in recent years. Asia Pacific holds majority of the market share, closely followed by Europe. The demand for RTD tea and coffee is projected to increase in North America due to rising...

Marine-Derived Pharmaceuticals Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast, 2012 - 2018

By - Transparency Market Research

Description Marine derived pharmaceuticals are the drugs and other pharmacological substances which are made from extracting elements present in marine life. Although the concept of marine ethnomedicine dates back to the 18th and 19th century, actual exploratory work on marine pharmacology began in the mid and late 1960s when groups of chemists in the United States, Japan, and Europe began to explore sponges, marine algae, and other forms of marine life for their medicinal properties. At present there are several marine-derived pharmaceuticals available in the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-618-1030
Email: sales@researchmoz.us

Select License type:

Share this report

Scoop.it

Latest Reports

Sep 14, 2012

The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...

Now At-Home TB Diagnosis Looks Possible

Sep 14, 2012

According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...

China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects

Sep 14, 2012

Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...

Battling against flu, vaccination necessary for health workers

Sep 14, 2012

To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...

Japan to Cut Import Duties on Indian Generic Drugs Imports

Sep 14, 2012

The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...